Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Iwamoto

Showing results (421-430 of 459) with videos related to

Pageof 46
Sort By:
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
British Journal of Neurosurgery|January 15, 2020
Surgery plus adjuvant radiotherapy for primary central nervous system lymphomaConnor J Kinslow, Ali I Rae, Alfred I Neugut, et al.
Epidemiology and Infection|May 1, 2010
Multistate outbreak of Escherichia coli O157:H7 infections associated with a national fast-food chain, 2006: a study incorporating epidemiological and food source traceback resultsS V Sodha, M Lynch, K Wannemuehler, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsL A Wenning, A S Petry, J T Kost, et al.
Journal of Neuro-Oncology|December 22, 2017
Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastomaDeborah R Smith, Cheng-Chia Wu, Heva J Saadatmand, et al.
Neurosurgery|April 17, 2018
Craniotomy and Survival for Primary Central Nervous System LymphomaAli I Rae, Amol Mehta, Michael Cloney, et al.
Cancer|April 21, 2012
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or olderJacob G Scott, Luc Bauchet, Tyler J Fraum, et al.
JAMA Oncology|May 18, 2023
Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating ChemotherapyConnor J Kinslow, Ann Mercurio, Prashanth Kumar, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 1, 1996
[Development of quality of life questionnaire for patients with colorectal cancer in surgical area--a study of reliability and validity of Tokyo Yamabuki Forum Version]Y Ishihara, S Maruyama, A Yagita, et al.
Neuro-Oncology|June 29, 2024
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomasConnor J Kinslow, Soumyajit Roy, Fabio M Iwamoto, et al.
Pageof 46

Showing results (421-430 of 459) with videos related to

Sort By:
Pageof 46
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
British Journal of Neurosurgery|January 15, 2020
Surgery plus adjuvant radiotherapy for primary central nervous system lymphomaConnor J Kinslow, Ali I Rae, Alfred I Neugut, et al.
Epidemiology and Infection|May 1, 2010
Multistate outbreak of Escherichia coli O157:H7 infections associated with a national fast-food chain, 2006: a study incorporating epidemiological and food source traceback resultsS V Sodha, M Lynch, K Wannemuehler, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsL A Wenning, A S Petry, J T Kost, et al.
Journal of Neuro-Oncology|December 22, 2017
Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastomaDeborah R Smith, Cheng-Chia Wu, Heva J Saadatmand, et al.
Neurosurgery|April 17, 2018
Craniotomy and Survival for Primary Central Nervous System LymphomaAli I Rae, Amol Mehta, Michael Cloney, et al.
Cancer|April 21, 2012
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or olderJacob G Scott, Luc Bauchet, Tyler J Fraum, et al.
JAMA Oncology|May 18, 2023
Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating ChemotherapyConnor J Kinslow, Ann Mercurio, Prashanth Kumar, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 1, 1996
[Development of quality of life questionnaire for patients with colorectal cancer in surgical area--a study of reliability and validity of Tokyo Yamabuki Forum Version]Y Ishihara, S Maruyama, A Yagita, et al.
Neuro-Oncology|June 29, 2024
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomasConnor J Kinslow, Soumyajit Roy, Fabio M Iwamoto, et al.
Pageof 46